Navigation Links
Bavarian Nordic Publishes its Annual Results 2008

contract. In 2009 we will have a continued strong focus on fulfilling this contract as well as a strong focus on preparing for the Phase III studies that we expect to initiate with both IMVAMUNE(R) and PROSTVAC(TM) in 2010."

Strong foundation for future growth and earnings

Despite the financial crisis and an economic slowdown, Bavarian Nordic recorded a positive development in 2008, and has laid a strong foundation for further value creation in 2009 and the years ahead. The expected positive development is based on the following elements:

    - Two vaccines moving into Phase III trials

    - Strong financial position

    - Profitable ongoing development and procurement contracts with a value
      of more than DKK 3.5 billion

    - Expectations to the US government's exercise of the contract option for
      additional development and procurement, worth more than DKK 6 billion

    - Ongoing contracts with countries outside USA

    - Partnership with the NCI, a world leading cancer research organisation

    - Strong patent portfolio

    - Pipeline with promising results

    - Future licensing agreement for PROSTVAC(TM)

    - The world's only manufacturing facility dedicated to the
      commercial-scale production of MVA based vaccines

    Important events after the balance sheet date
    IMVAMUNE(R) - end-of-Phase II meeting held with the FDA

After concluding the Phase II development of IMVAMUNE(R), Bavarian Nordic held an end-of-Phase-II meeting with the US health authorities (FDA) in the beginning of 2009 in order to discuss the Phase III study design. The meeting was a success and there was an open and highly constructive discussion with the FDA. Based on the meeting, Phase III studies are expected to be initiated in 2010.

The outcome of the meeting has no impact on the delivery of vaccines to the Strategic National Stockpile (SNS) under the RFP-

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
(Date:10/7/2015)... ... October 07, 2015 , ... The ... present a public educational seminar on the latest advances in adult stem cell ... pm – 3:00 pm at the Hilton Dallas/Southlake Town Square in Southlake, Texas. ...
(Date:10/7/2015)... RESEARCH TRIANGLE PARK, N.C. , Oct. 7, 2015 /PRNewswire/ ... of the campaign, TRL has committed to donating a ... of current liver research and hepatology practices. ... to furthering liver research in a variety of ways; ... to scientists around the world, collaborating with researchers in ...
(Date:10/7/2015)... ... 07, 2015 , ... ReliantHeart, Inc. the manufacturer of the ... Platforms, and Michael Ward of Wrenward Medical Systems to its Board of Directors. ... is Executive Vice President of Strategic Relationships and Operations, and a member of ...
(Date:10/6/2015)... , Oct. 6, 2015 CohBar, Inc. (OTCQX: ... therapeutics (MBTs) to treat diseases associated with aging, today ... Albion Fitzgerald , is now available for on-demand ... --> --> LINK: ... --> CohBar,s presentation will be available 24/7 ...
Breaking Biology Technology:
... steam methane reforming reactor, where ,methane and steam meet to ... at core of the reactor. Both photos courtesy of Modine ... ChevronTexaco Technology Ventures have presented a paper at the ... reactor that uses steam to extract hydrogen from natural gas. ...
... Bob Weisenberg read a lot of books on management and ... way through yet another book, he realized he had read ... the software industry, Weisenberg says the way to excel at ... number of skills, not by reading more books about it. ...
... noted UW-Madison biotech researchers, including stem-cell pioneer James ... house a new drug screening company in Madison's ... with Tactics II Ventures LP, a venture capital ... UW researchers Thomson, Craig January and Timothy Kamp ...
Cached Biology Technology:
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... , Sept. 29, 2015 News ... productivity while also saving energy , Minimized design ... Low Power Active Mode and embedded Fujitsu PalmSecure authentication ... Fujitsu today shows that good things come ... refreshed models to its enterprise desktop and mobile portfolio. ...
Breaking Biology News(10 mins):
... release is available in Spanish . ... (UPV/EHU), has developed genetic-molecular tools, with the intention of completing ... equine breeds in the Basque Country Autonomous Community (CAPVEAE) and ... DNA sequence) and certain SNPs (a kind of variation in ...
... This release is available in French . ... Canadians of French ancestry who suffer a rare genetic disease, ... making a breakthrough that will improve our understanding of many ... of body parts and cancer. "As a result of the ...
... ANN ARBOR, Mich.---In the mating game, some female mites are ... Michigan and the Russian Academy of Sciences suggests. The evidence ... Baltic amber. In a paper published March 1 in ... Pavel Klimov and Ekaterina Sidorchuk describe an extinct mite species ...
Cached Biology News:
... a buffered anti-freeze environment for enzyme conjugated ... liquid, low viscosity solution at -20C ... and sampling is convenient , Contains ... storage Protect enzyme conjugates during storage ...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... SearchLight® Array Analyst Software has been ... arrays. Mathematical algorithms allow the software to ... spot within each well of an ELISA ... SearchLight® Array Analyst Software has been customized ...
... fully automated hybridization of microarrays on slides. ... designed to offer researchers improved reproducibility, superior ... a wide range of applications. Incubations ... denaturations of up to 99C. The possibility ...
Biology Products: